{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:54:29Z","timestamp":1791125669829,"version":"4.1.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Folicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, shows considerable heterogeneity in its clinical behavior, representative of a biology that appears increasingly complex and diverse. As our knowledge of the molecular basis of FL increases, we strive for an integration between the bench and clinic that yields treatments based on our scientific understanding and biomarkers that allow us to prescribe treatment rationally.<\/jats:p><jats:p>In Section I, Dr. Randy Gascoyne describes the histologic, cytogenetic and biologic features of FL that underlie its clinical variability. Key aspects of the pathologic diagnosis of FL that have particular relevance to the clinician are highlighted. A proposed model for follicular lymphomagenesis and diffuse large B cell lymphoma transformation has emerged and continues to evolve as the molecular story unfolds. A biologic basis for clinical outcome in FL also appears to be forthcoming.<\/jats:p><jats:p>In Section II, Dr. Jane Winter addresses the complex process of selecting among the many treatment options for patients with FL. Previously a simple matter of deciding between oral or intravenous alkylators, clinicians and patients must now struggle to choose among vastly different approaches ranging from \u201cwatch and wait\u201d to stem cell transplantation. The introduction of rituximab and radioimmunoconjugates is changing the treatment paradigm, but the optimal approach to integrating these and other new agents remains to be determined. At every decision point, the best approach is always a clinical trial.<\/jats:p><jats:p>In Section III, Dr. Koen Van Besien provides a well-documented update on outcomes associated with autologous and allogeneic stem cell transplantation for FL. The results of trials of autologous stem cell transplantation in first remission and recent data supporting a role for graft purging are discussed. Based on the premise that a graft-versus-lymphoma effect is operative in FL, reduced-intensity allogeneic transplantation is the preferred approach in many cases, and recently reported results are summarized. Criteria for patient selection and the optimal role of transplantation in the overall therapeutic plan for the patient with FL are presented.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.203","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"203-220","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Low-Grade Lymphoma"],"prefix":"10.1182","volume":"2004","author":[{"given":"Jane N.","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Besien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021215284592000_R1","doi-asserted-by":"crossref","unstructured":"Anonymous. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89:3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2020021215284592000_R2","doi-asserted-by":"crossref","unstructured":"Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846\u2013852.","DOI":"10.1097\/00000478-200006000-00010"},{"key":"2020021215284592000_R3","doi-asserted-by":"crossref","unstructured":"Aster JC, Longtine JA. Detection of BCL2 rearrangements in follicular lymphoma. Am J Pathol. 2002;160:759\u2013763.","DOI":"10.1016\/S0002-9440(10)64897-3"},{"key":"2020021215284592000_R4","doi-asserted-by":"crossref","unstructured":"Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363\u20132367.","DOI":"10.1182\/blood-2002-07-2298"},{"key":"2020021215284592000_R5","doi-asserted-by":"crossref","unstructured":"Vergier B, Belaud-Rotureau MA, Benassy MN, et al. Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas. Am J Surg Pathol. 2004;28:748\u2013755.","DOI":"10.1097\/01.pas.0000126775.27698.6e"},{"key":"2020021215284592000_R6","doi-asserted-by":"crossref","unstructured":"Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood. 2002;99:3376\u20133382.","DOI":"10.1182\/blood.V99.9.3376"},{"key":"2020021215284592000_R7","doi-asserted-by":"crossref","unstructured":"Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99:3806\u20133812.","DOI":"10.1182\/blood.V99.10.3806"},{"key":"2020021215284592000_R8","doi-asserted-by":"crossref","unstructured":"Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer. 2001;30:375\u2013382.","DOI":"10.1002\/gcc.1103"},{"key":"2020021215284592000_R9","doi-asserted-by":"crossref","unstructured":"Lestou VS, Gascoyne RD, Sehn L, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol. 2003;122:745\u2013759.","DOI":"10.1046\/j.1365-2141.2003.04502.x"},{"key":"2020021215284592000_R10","doi-asserted-by":"crossref","unstructured":"Viardot A, Moller P, Hogel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol. 2002;20:4523\u20134530.","DOI":"10.1200\/JCO.2002.12.006"},{"key":"2020021215284592000_R11","doi-asserted-by":"crossref","unstructured":"Hoglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39:195\u2013204.","DOI":"10.1002\/gcc.10314"},{"key":"2020021215284592000_R12","doi-asserted-by":"crossref","unstructured":"Horsman DE, Okamoto I, Ludkovski O, et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol. 2003;120:424\u2013433.","DOI":"10.1046\/j.1365-2141.2003.04086.x"},{"key":"2020021215284592000_R13","doi-asserted-by":"crossref","unstructured":"Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade IIIB includes three cytogenetically defined subgroups with primary t(14;18), 3q27 or other translocations; t(14;18) and 3q27 are mutually exclusive. Blood. 2003;101:1148\u20131154.","DOI":"10.1182\/blood.V101.3.1149"},{"key":"2020021215284592000_R14","doi-asserted-by":"crossref","unstructured":"Raghavan SC, Swanson PC, Wu X, Hsieh CL, Lieber MR. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature. 2004;428:88\u201393.","DOI":"10.1038\/nature02355"},{"key":"2020021215284592000_R15","doi-asserted-by":"crossref","unstructured":"Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351:250\u2013259.","DOI":"10.1056\/NEJMoa033153"},{"key":"2020021215284592000_R16","doi-asserted-by":"crossref","unstructured":"Aarts WM, Bende RJ, Bossenbroek JG, Pals ST, van Noesel CJ. Variable heavy-chain gene analysis of follicular lymphomas: subclone selection rather than clonal evolution over time. Blood. 2001;98:238\u2013240.","DOI":"10.1182\/blood.V98.1.238"},{"key":"2020021215284592000_R17","doi-asserted-by":"crossref","unstructured":"Zha H, Raffeld M, Charboneau L, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004;84:235\u2013244.","DOI":"10.1038\/labinvest.3700051"},{"key":"2020021215284592000_R18","doi-asserted-by":"crossref","unstructured":"Hardianti MS, Tatsumi E, Syampurnawati M, et al. Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. Leukemia. 2004;18:826\u2013831.","DOI":"10.1038\/sj.leu.2403323"},{"key":"2020021215284592000_R19","doi-asserted-by":"crossref","unstructured":"Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002;99:282\u2013289.","DOI":"10.1182\/blood.V99.1.282"},{"key":"2020021215284592000_R20","doi-asserted-by":"crossref","unstructured":"Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A. 2002;99:8886\u20138891.","DOI":"10.1073\/pnas.132253599"},{"key":"2020021215284592000_R21","doi-asserted-by":"crossref","unstructured":"Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A. 2003;100(12):7259\u20137264.","DOI":"10.1073\/pnas.1137463100"},{"key":"2020021215284592000_R22","doi-asserted-by":"crossref","unstructured":"Petersen PM, Gospodarowitz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. Proc ASCO. 2004;23:561.","DOI":"10.1200\/jco.2004.22.90140.6521"},{"key":"2020021215284592000_R23","doi-asserted-by":"crossref","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454\u20131459.","DOI":"10.1200\/JCO.2004.10.086"},{"key":"2020021215284592000_R24","doi-asserted-by":"crossref","unstructured":"Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21:2115\u20132122.","DOI":"10.1200\/JCO.2003.07.111"},{"key":"2020021215284592000_R25","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet. 2003;362:516\u2013522.","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"2020021215284592000_R26","doi-asserted-by":"crossref","unstructured":"Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2003;21:5\u201315.","DOI":"10.1200\/jco.2003.05.128"},{"key":"2020021215284592000_R27","doi-asserted-by":"crossref","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u20131265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"2020021215284592000_R28","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller E, Ryan T, et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO. 2004;23:556.","DOI":"10.1200\/jco.2004.22.90140.6502"},{"key":"2020021215284592000_R29","doi-asserted-by":"crossref","unstructured":"Fisher RL, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin\u2019s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol. 2000;18:2010\u20132016.","DOI":"10.1200\/JCO.2000.18.10.2010"},{"key":"2020021215284592000_R30","unstructured":"Hiddemann W, Dreyling MH, Forstpointer R, et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma\u2014results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood. 2003;102:104a."},{"key":"2020021215284592000_R31","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood. 2004;103:4416\u20134423.","DOI":"10.1182\/blood-2003-10-3411"},{"key":"2020021215284592000_R32","unstructured":"Hainsworth JD, Lichty S, Greco A. Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma (NHL) responding to single agent rituximab: a randomized trial of the Minnie Pearl Cancer Research Network [abstract]. Blood. 2003;102:69a."},{"key":"2020021215284592000_R33","unstructured":"Czuczman M, Grillo-Lopez AJ, LoBuglio AI, et al. Patients with low-grade NHL treated with rituximab and CHOP experience prolonged clinical and molecular remission [abstract]. Blood. 2003;102:411a."},{"key":"2020021215284592000_R34","unstructured":"Marcus R, Imrie K, Belch A, et al. An international, multi centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III\/IV follicular non-Hodgkins lymphoma [abstract]. Blood. 2003;102:28a."},{"key":"2020021215284592000_R35","unstructured":"Dreyling MH, Forstpointer R, Repp R, et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma\u2014final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood. 2003;102:103a."},{"key":"2020021215284592000_R36","doi-asserted-by":"crossref","unstructured":"Vose JM. Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin\u2019s lymphoma. Oncologist. 2004;9:160\u2013172.","DOI":"10.1634\/theoncologist.9-2-160"},{"key":"2020021215284592000_R37","doi-asserted-by":"crossref","unstructured":"Witzig TE. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin\u2019s lymphoma. Semin Oncol. 2003;30:11\u201316.","DOI":"10.1053\/j.seminoncol.2003.10.007"},{"key":"2020021215284592000_R38","doi-asserted-by":"crossref","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:2453\u20132463.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2020021215284592000_R39","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2001;19:3918\u20133928.","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"2020021215284592000_R40","unstructured":"Kaminski MS, Tuck M, Regan D, et al. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar) [abstract]. Blood. 2002;100:356a."},{"key":"2020021215284592000_R41","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606\u20131612.","DOI":"10.1182\/blood-2003-01-0287"},{"key":"2020021215284592000_R42","unstructured":"Tse WM, Lazarus HM, van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. In press."},{"key":"2020021215284592000_R43","doi-asserted-by":"crossref","unstructured":"Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood. 2002;100:1141\u20131152.","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152"},{"key":"2020021215284592000_R44","doi-asserted-by":"crossref","unstructured":"Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood. 1999;94:3325\u20133333.","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"2020021215284592000_R45","doi-asserted-by":"crossref","unstructured":"Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918\u20133927.","DOI":"10.1200\/JCO.2003.10.023"},{"key":"2020021215284592000_R46","doi-asserted-by":"crossref","unstructured":"Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival infollicular lymphoma - results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood. Jul 6 2004. Epub ahead of print.","DOI":"10.1182\/blood-2004-03-0982"},{"key":"2020021215284592000_R47","unstructured":"Deconinck E, Foussard C, Bertrand P, et al. Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 Trial [abstract]. Blood. 2003;646."},{"key":"2020021215284592000_R48","doi-asserted-by":"crossref","unstructured":"van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521\u20133529.","DOI":"10.1182\/blood-2003-04-1205"},{"key":"2020021215284592000_R49","doi-asserted-by":"crossref","unstructured":"Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351\u20132357.","DOI":"10.1182\/blood-2003-02-0622"},{"key":"2020021215284592000_R50","doi-asserted-by":"crossref","unstructured":"Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559\u20131565.","DOI":"10.1182\/blood-2002-02-0621"},{"key":"2020021215284592000_R51","doi-asserted-by":"crossref","unstructured":"Fouillard L, Laporte JP, Labopin M, et al. Autologous stem-cell transplantation for non-Hodgkin\u2019s lymphomas: the role of graft purging and radiotherapy posttransplantation\u2014results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol. 1998;16:2803\u20132816.","DOI":"10.1200\/JCO.1998.16.8.2803"},{"key":"2020021215284592000_R52","doi-asserted-by":"crossref","unstructured":"Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000;18:527\u2013536.","DOI":"10.1200\/JCO.2000.18.3.527"},{"key":"2020021215284592000_R53","doi-asserted-by":"crossref","unstructured":"Bierman PJ, Sweetenham JW, Loberiza FM, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma: a comparison with allogeneic and autologous transplantation. J Clin Oncol. 2003;21:3744\u20133753.","DOI":"10.1200\/JCO.2003.08.054"},{"key":"2020021215284592000_R54","doi-asserted-by":"crossref","unstructured":"Flinn IW, O\u2019Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2000;6:628\u2013632.","DOI":"10.1016\/S1083-8791(00)70028-0"},{"key":"2020021215284592000_R55","doi-asserted-by":"crossref","unstructured":"Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2004;33:921\u2013923.","DOI":"10.1038\/sj.bmt.1704467"},{"key":"2020021215284592000_R56","doi-asserted-by":"crossref","unstructured":"Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015\u20132023.","DOI":"10.1182\/blood-2002-04-1261"},{"key":"2020021215284592000_R57","doi-asserted-by":"crossref","unstructured":"Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients. J Clin Oncol. 2003;21:897\u2013906.","DOI":"10.1200\/JCO.2003.07.113"},{"key":"2020021215284592000_R58","doi-asserted-by":"crossref","unstructured":"Khouri IF, Champlin RE. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol. 2004;31:22\u201326.","DOI":"10.1053\/j.seminoncol.2003.10.017"},{"key":"2020021215284592000_R59","doi-asserted-by":"crossref","unstructured":"Mandigers CM, Verdonck LF, Meijerink JP, et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159\u20131163.","DOI":"10.1038\/sj.bmt.1704290"},{"key":"2020021215284592000_R60","doi-asserted-by":"crossref","unstructured":"Robinson SP, Mackinnon S, Goldstone A, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310\u20134316.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2020021215284592000_R61","doi-asserted-by":"crossref","unstructured":"Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428\u2013434.","DOI":"10.1182\/blood-2003-05-1406"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/203\/1634560\/203_220ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/203\/1634560\/203_220ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T05:28:56Z","timestamp":1624944536000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/203\/18701\/LowGrade-Lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.203","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}